Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Labeling DNA Probes

Labeling DNA Probes

DNA probes are fragments of DNA labeled with a reporter tag to enable their detection or purification. The resulting labeled DNA probes can then hybridize to target nucleic acid sequences through complementary base-pairing, and may be used to recover or identify these regions.
Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile.

International journal of molecular sciences·2024

Same author

Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?

International journal of molecular sciences·2023

Same author

Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.

Clinical nuclear medicine·2020

Same author

Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.

Clinical nuclear medicine·2020

Same author

Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.

Case reports in endocrinology·2020

Same author

GIP receptor: Expression in neuroendocrine tumours, internalization, signalling from endosomes and structure-function relationship studies.

Peptides·2019

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Peptide-based probes for cancer imaging.

Jean Claude Reubi¹, Helmut R Maecke

¹University of Berne, Berne, Switzerland. reubi@pathology.unibe.ch

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|October 18, 2008

Summary

Peptide receptor imaging in cancer is advancing with new tracers for various tumors. These radiolabeled probes enable precise in vivo imaging for neuroendocrine tumors and other cancers using SPECT/CT and PET/CT.

Area of Science:

Oncology
Radiochemistry
Molecular Imaging

Background:

Overexpression of regulatory peptide receptors is common in human cancers.
These receptors serve as molecular targets for in vivo imaging using radiolabeled peptide probes.
Somatostatin-derived tracers have been successfully used for imaging sst2-overexpressing neuroendocrine tumors for nearly two decades.

Purpose of the Study:

To review the development and application of peptide receptor-based imaging agents in oncology.
To highlight advancements in somatostatin analogs and emerging tracers for various cancer types.
To discuss the application of these imaging techniques in both SPECT/CT and PET/CT.

Main Methods:

Development and application of radiolabeled peptide probes targeting specific receptors.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a ⁶⁸Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Jun 28, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a ⁶⁸Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Utilizing somatostatin analogs with broader receptor subtype profiles or antagonistic properties.

Exploring emerging tracers for cholecystokinin/gastrin, GLP-1, bombesin, neuropeptide-Y, and Arg-Gly-Asp receptors.

Main Results:

Established clinical application of somatostatin tracers for neuroendocrine tumors.
Ongoing development of second- and third-generation somatostatin analogs.
Emerging tracers show promise for imaging prostate, breast cancers, and neoangiogenesis.

Conclusions:

Peptide receptor imaging is a valuable tool in oncology, with ongoing innovation in tracer development.
Advanced tracers offer broader targeting capabilities and improved imaging for diverse cancers.
SPECT/CT and PET/CT are key modalities for applying these peptide-based imaging strategies.